Development of New Potential Inhibitors of β1 Integrins through In Silico Methods-Screening and Computational...

Area of Science:

• Biochemistry
• Pharmacology
• Structural Biology

Background:

• Integrins are key transmembrane receptors involved in numerous biological processes.
• Integrin blockers, particularly peptidomimetic ligands, offer therapeutic potential.
• α4β1 integrins and VLA-4 are significant targets in various diseases.

Purpose of the Study:

• To design and develop novel β1 integrin antagonists.
• To optimize existing α4β1 antagonists for enhanced affinity and therapeutic potential.
• To identify new drug candidates targeting VLA-4.

Main Methods:

• Utilized modeled receptors based on aligned crystallographic structures.
• Performed molecular docking of lead compounds (BIO1211, BIO5192, TCS2314) with receptors.
• Optimized ligand-receptor complexes by modifying substituents and assessing pharmacokinetic properties.
• Generated and evaluated over 200 derivatives of BIO5192.

Main Results:

• Identified an essential salt bridge interaction between BIO5192 and the integrin's Mg²⁺ MIDAS ion.
• Discovered that retaining the pyrrolidine core of the ligand is crucial for affinity.
• Generated novel BIO5192 derivatives with predicted higher affinity to α4β1.
• Molecule 1592 demonstrated favorable pharmacokinetic profiles and higher predicted affinity to VLA-4 compared to BIO5192.

Conclusions:

• The study successfully generated novel α4β1 integrin antagonists with improved properties.
• Molecule 1592 emerged as a promising drug candidate due to its high predicted affinity and suitable pharmacokinetics.
• The findings highlight the importance of specific structural features, like the pyrrolidine core and salt bridge interactions, for developing effective integrin antagonists.